— Shares of biopharmaceutical company AbbVie shed more than 1% after the CEO said at the JPMorgan Healthcare Conference that it expects the loss of exclusivity of Humira, its drug for
arthritis and psoriasis, to affect the company's performance in the near term, according to a report from Bloomberg. The company does not anticipate a decline in 2024 earnings, however.
이 소식을 빠르게 읽을 수 있도록 요약했습니다. 뉴스에 관심이 있으시면 여기에서 전문을 읽으실 수 있습니다. 더 많은 것을 읽으십시오:
대한민국 최근 뉴스, 대한민국 헤드 라인
Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.
Stocks making the biggest moves midday: Bed Bath & Beyond, Coinbase, Virgin Orbit and moreThese are the stocks posting the largest moves midday.
출처: CNBC - 🏆 12. / 72 더 많은 것을 읽으십시오 »
UBS sees these retail stocks winning from a potential Bed Bath & Beyond bankruptcyDoubts about Bed Bath & Beyond's future opens a door for other retailers to pick up market share, says UBS
출처: CNBC - 🏆 12. / 72 더 많은 것을 읽으십시오 »
Bed Bath & Beyond jumps 50% to lead last gasp rally in meme stocks; AMC gains 15%A group of highly speculative stocks rallied double digits on Wednesday as retail investors pushed meme names up again in the new year following a dismal 2022.
출처: CNBC - 🏆 12. / 72 더 많은 것을 읽으십시오 »